Video

Dr. Smith on the Guiding Principles for Treating iNHL

Sonali M. Smith, MD, discusses the prognosis of patients with indolent non-Hodgkin lymphomas.

Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, discusses the prognosis of patients with indolent non-Hodgkin lymphomas (iNHLs).

Patients with iNHL can be categorized to different subsets of the disease, such as follicular lymphoma, Smith says. For treatment, there are guiding principles physicians can use to help select the appropriate treatment for each patient.

It is important to remember these are chronic malignancies, so patients can live for a very long time. With the long-term expected survival, Smith says it is important to think of both the short-term and long-term side effects of treatment for patients with iNHL. An important principle is that treating patients before they need therapy, however, does not help patients live longer or better, according to the data we have to date, Smith says.

Related Videos
Andrew Ip, MD
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, break down the current treatment landscape for relapsed/refractory follicular lymphoma.
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP